Drugs / VRC-EBOMVA079-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02408913 | Mar 2015 → Apr 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-EBOMVA079-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02408913 ↗ |
| Known as | MVA-EbolaZ | “VRC-EBOMVA079-00-VP (MVA-EbolaZ)” NCT02408913 ↗ |
| Modality | Vaccine | “two new vaccines VRC-EBOMVA079-00-VP (MVA-EbolaZ) and VRC-EBOADC069-00VP ( cAd3-EBO )” NCT02408913 ↗ |
| Route | Intramuscular | “will be administered intramuscularly (IM) with needle and syringe” NCT02408913 ↗ |